Table 1.
Subject characteristics
| Cell culture
|
Immunohistochemistry
|
|||
|---|---|---|---|---|
| Sample ID | Diagnosis | Sample ID | Cycle phase | Diagnosis |
| 298 | No endo (P) | 441 | PE | No endo (Fb, M) |
| 316 | No endo (P, A, Fb) | 426 | PE | No endo (Dm, Dp, M) |
| 229 | No endo (PP) | 539 | PE | No endo (Fb) |
| 236 | No endo (POP) | 588 | PE | Endo, stage II |
| 275 | No endo (Fb) | 634 | PE | Endo, stage II |
| 277 | No endo (Fb) | 697 | PE | Endo, stage IV |
| 285 | No endo (Fb) | 114 | PE | Endo, stage IV |
| 293 | No endo (Fb) | 123 | PE | Endo, stage IV |
| 326 | No endo (Fb) | |||
| 310 | No endo (Fb, Ec) | 650 | ES | No endo (Fb, M) |
| 456 | ES | No endo (Fb, Dm, Mm) | ||
| 233 | Endo, stage II | 458 | ES | No endo (M) |
| 272 | Endo, stage II–IV (A) | 680 | ES | No endo (UVP) |
| 242 | Endo, stage I–II | 24 | ES | No endo (M) |
| 243 | Endo, stage II–III (A, Fb) | 607 | ES | Endo, stage IV |
| 279 | Endo, stage II–IV | 599 | ES | Endo, stage IV |
| 288 | Endo, stage IV | 591 | ES | Endo, stage I |
| 307 | Endo, stage IV | 625 | ES | Endo, unstaged |
| 314 | Endo, stage IV | 471 | ES | Endo, stage III–IV |
| 375 | Endo, stage IV | 127 | ES | Endo, stage IV |
| 381 | Endo, stage IV | |||
| 271 | Endo, stage IV (A) | 626 | MS | No endo (Cc, Rc) |
| 305 | Endo, stage IV (Fb) | 465 | MS | No endo (Fb) |
| 665 | MS | No endo (Fb, M, PP, A) | ||
| 635 | MS | Endo, stage II | ||
| 546 | MS | Endo, stage II (A) | ||
| 37 | MS | Endo, stage III | ||
| 526 | MS | Endo, stage III–IV (A) | ||
| 462 | LS | No endo (SUI) | ||
| 614 | LS | No endo (UVP) | ||
| 648 | LS | No endo (Fb, SUI) | ||
| 576 | LS | No endo (POC) | ||
A, Adenomyosis; Cc, cystocele; Dm, dysmenorrhea; Dp, dysparenuria; Ec, enterocele; Endo, endometriosis; Fb, uterine fibroids; M, menorrhagia; Mm, menometrorrhagia; No endo, without endometriosis; P, polyp; POC, paratubal ovarian cyst; POP, pelvic organ prolapse; PP, pelvic pain; Rc, rectocele; SUI, stress urinary incontinence; UVP, uterovaginal prolapse.